BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36862155)

  • 1. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.
    Untiedt S; Rolf D; Scobioala S; Wolters H; Elsayad K; Oertel M; Kittel C; Pascher A; Rijcken E; Ullerich H; Glasbrenner B; Eich HT
    Strahlenther Onkol; 2023 Aug; 199(8):749-760. PubMed ID: 36862155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Outcomes With Dose Escalation Using Modern Radiotherapy Techniques: A Retrospective Review of Anal Cancer Treated at a Large Academic Institution Between 2010 and 2016.
    Murchison SC; DeVries KJ; Atrchian S
    Cureus; 2020 Oct; 12(10):e10989. PubMed ID: 33209545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
    Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
    Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.
    Koerber SA; Slynko A; Haefner MF; Krug D; Schoneweg C; Kessel K; Kopp-Schneider A; Herfarth K; Debus J; Sterzing F
    Radiat Oncol; 2014 May; 9():113. PubMed ID: 24886574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy and cisplatin-based chemotherapy for anal cancer: long-term outcomes at a single institution.
    Gerardi MA; Zerella MA; Bergamaschi L; Ferrari A; Arculeo S; Bagnardi V; Frassoni S; Petz W; Fodor C; Emiro F; Cattani F; Leonardi MC; Zampino MG; Jereczek-Fossa BA
    Int J Colorectal Dis; 2023 May; 38(1):123. PubMed ID: 37162567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience.
    Jethwa KR; Day CN; Sandhyavenu H; Gonuguntla K; Harmsen WS; Breen WG; Routman DM; Garda AE; Hubbard JM; Halfdanarson TR; Neben-Wittich MA; Merrell KW; Hallemeier CL; Haddock MG
    Clin Transl Radiat Oncol; 2021 May; 28():17-23. PubMed ID: 33732911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy.
    Dell'Acqua V; Surgo A; Arculeo S; Zerella MA; Bagnardi V; Frassoni S; Zampino MG; Ravenda PS; Rotundo MS; Kraja F; Kobiela J; Spychalski P; Fodor C; Gerardi MA; Cattani F; Bazani A; Petz W; Glynne-Jones R; Orecchia R; Leonardi MC; Jereczek-Fossa BA
    Int J Colorectal Dis; 2020 Apr; 35(4):685-694. PubMed ID: 32036405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
    Leiker AJ; Wang CJ; Sanford NN; Aguilera TA; Karri S; Beg MS; Kazmi SA; Olson C; Matthews JA; Abdelnaby A; Meyer JJ; Folkert MR
    Am J Clin Oncol; 2020 Oct; 43(10):701-708. PubMed ID: 32694298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
    de Meric de Bellefon M; Lemanski C; Castan F; Samalin E; Mazard T; Lenglet A; Demontoy S; Riou O; Llacer-Moscardo C; Fenoglietto P; Aillères N; Thezenas S; Debrigode C; Vieillot S; Gourgou S; Azria D
    Radiother Oncol; 2020 Mar; 144():141-147. PubMed ID: 31809980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
    Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
    Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-tailored Anal Canal Radiotherapy (HIT-ART): Outcomes of a 10-Year Single Center Clinical Experience.
    Manfrida S; Fionda B; Mariani S; Luca V; Bertolini R; Barbaro B; Chiloiro G; Frascino V; Tagliaferri L; Gambacorta MA
    In Vivo; 2024; 38(3):1306-1315. PubMed ID: 38688632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
    Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
    Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
    Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer.
    Lerman J; Hennequin C; Etienney I; Abramowitz L; Goujon G; Gornet JM; Guillerm S; Aparicio T; Valverde A; Cattan P; Quéro L
    Eur J Cancer; 2020 Dec; 141():143-151. PubMed ID: 33137590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.